Promising Penny Stocks To Consider In July 2025

As the U.S. market navigates recent fluctuations, with major indices like the S&P 500 and Nasdaq Composite reaching record highs before a slight downturn, investors are keenly watching developments on tariffs and other economic policies. In such a climate, penny stocks—often representing smaller or newer companies—continue to capture attention for their potential value and growth opportunities. Despite being an older term, these stocks can offer affordability coupled with significant upside when backed by strong financials.

Top 10 Penny Stocks In The United States

Click here to see the full list of 422 stocks from our US Penny Stocks screener.

Let's review some notable picks from our screened stocks.

OmniAb (OABI)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: OmniAb, Inc. is a biotechnology company that licenses discovery research technology to pharmaceutical and biotech companies, as well as academic institutions, for therapeutic discovery across the United States, Europe, Japan, China, and Canada; it has a market cap of approximately $236.11 million.

Operations: The company's revenue is primarily generated from research services, amounting to $26.74 million.

Market Cap: $236.11M

OmniAb, Inc. is a biotechnology company with a market cap of US$236.11 million, generating US$4.15 million in revenue for Q1 2025, showing slight growth from the previous year. Despite being unprofitable with a net loss of US$18.2 million and negative return on equity, it remains debt-free and has sufficient cash runway for over a year based on current free cash flow. Recent strategic moves include launching the xPloration Partner Access Program and forming an alliance with VERAXA Biotech AG to develop bispecific antibody drug conjugates targeting solid tumors, potentially enhancing its future revenue streams.

• Take a closer look at OmniAb's potential here in our financial health report.
• Learn about OmniAb's future growth trajectory here.

4D Molecular Therapeutics (FDMT)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: 4D Molecular Therapeutics, Inc. is a late-stage biotechnology company focused on developing adeno-associated virus vectors through its proprietary platform, Therapeutic Vector Evolution, operating in the Netherlands and the United States with a market cap of $196.42 million.

Operations: The company generates revenue from its biotechnology segment, amounting to $0.023 million.

Market Cap: $196.42M

4D Molecular Therapeutics, Inc., with a market cap of US$196.42 million, is a pre-revenue biotechnology firm focused on late-stage clinical trials for its 4D-150 therapy targeting wet age-related macular degeneration and diabetic macular edema. The company recently accelerated its Phase 3 trials, supported by cash reserves of US$458 million to sustain operations through 2028. Despite recent executive changes and workforce reductions aimed at cost savings of approximately US$15 million annually, the firm's stock was removed from multiple Russell Indexes in June 2025 due to performance metrics. It remains unprofitable with no significant revenue streams yet established.

• Dive into the specifics of 4D Molecular Therapeutics here with our thorough balance sheet health report.
• Understand 4D Molecular Therapeutics' earnings outlook by examining our growth report.

3D Systems (DDD)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: 3D Systems Corporation offers 3D printing and digital manufacturing solutions across various regions worldwide, with a market cap of $234.63 million.

Operations: The company's revenue is derived from two primary segments: Healthcare, contributing $185.64 million, and Industrial, generating $246.12 million.

Market Cap: $234.63M

3D Systems, with a market cap of US$234.63 million, recently joined several Russell Indexes, underscoring its visibility in the market despite ongoing challenges. The company has faced financial hurdles, including a significant drop in stock price following disappointing earnings and revenue shortfalls attributed to weakened customer spending and inventory issues. While it remains unprofitable with increasing losses over five years, 3D Systems' innovations in healthcare solutions have garnered FDA approval for bioprinting technologies. However, legal challenges loom due to allegations of misleading statements about its business resilience and revenue projections. The firm maintains a cash runway exceeding one year amidst high debt levels.

• Click here and access our complete financial health analysis report to understand the dynamics of 3D Systems.
• Gain insights into 3D Systems' outlook and expected performance with our report on the company's earnings estimates.

Make It Happen

• Unlock more gems! Our US Penny Stocks screener has unearthed 419 more companies for you to explore.Click here to unveil our expertly curated list of 422 US Penny Stocks.
• Want To Explore Some Alternatives? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com